NCT03462992 (MonoFIT+) is a clinical trial of MonoMark in Colorectal Cancer, sponsored by DNAlytics.

Who is sponsoring NCT03462992?

NCT03462992 is sponsored by DNAlytics.

What drugs are being tested in NCT03462992?

Interventions in NCT03462992: MonoMark.

What condition does NCT03462992 study?

NCT03462992 studies Colorectal Cancer.

Is NCT03462992 still recruiting?

NCT03462992 is currently status unknown. Last updated 13 March 2018.

Last reviewed 2018-03-13 · How we verify

NCT03462992: MonoFIT+

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peripheral Blood Monocytes as Predictive Marker for Colorectal Cancer Diagnosis: A Comparative Study of a Stool Based Versus Blood Based Screening Test

Status unknown Last updated 13 March 2018

What this trial tests

trial testing MonoMark in Colorectal Cancer in 250 participants. Status unknown.

Timeline

11 December 2012

Primary endpoint
21 December 2017

2 May 2018

Quick facts

Lead sponsor	DNAlytics
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	250
Start date	11 December 2012
Primary completion	21 December 2017
Estimated completion	2 May 2018
Sites	1 location across Belgium

Drugs / interventions tested

MonoMark

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

DNAlytics

Who can join

Adults 56 to 74, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this prospective study, the main goal is to evaluate the strength of Monomark -a monocyte-based transcriptomic test combined to a mathematical model- in patients with a positive FIT test. Therefore, in parallel to the routine FIT screening, blood samples will be harvested and the monocyte genetic profile will be determined. This fundamental study, will disclose the diagnostic power of a biomarker panel ("MonoMark") head to head with the well-established FIT diagnostic test, a core prerequisite for the routine use of this test as an alternative and more reliable CRC screening tool.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03462992 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by DNAlytics
Last refreshed: 13 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03462992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing